Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC - Concepedia

Concepedia

Publication | Closed Access

Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

148

Citations

47

References

2009

Year

Pamela N. Münster, Douglas C. Marchion, Elona Biçaku, Mira Lacevic, Jongphil Kim, Barbara A. Centeno, Adil Daud, Anthony Neuger, Susan Minton, Daniel M. Sullivan

Clinical Cancer Research

Abstract

Valproic acid is a clinically relevant HDAC inhibitor, and PBMCs may serve as a surrogate for tumor histone acetylation in solid tumor malignancies. HDAC2 should be further considered as a relevant therapeutic target.

References

	Year	Citations

Page 1